SCHEMBL6281960

SCHEMBL6281960

COc1ccc(Oc2ccc3c(cnn3-c3cccnc3)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 7/20 0.59
CYP11B1 P15538 4/20 0.53
SMO Q99835 2/20 0.44
CYP17A1 P05093 2/20 0.43
CYP19A1 P11511 1/20 0.43
NPBWR1 P48145 6/20 0.41
MCHR1 Q99705 3/20 0.41
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NR3C1 P04150 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6185201 0.88 CYP11B2 (0.59) CYP11B2CYP11B1SMONPBWR1MCHR1
SCHEMBL6282015 0.80 CYP11B1 (0.61) CYP11B2CYP11B1NPBWR1NPSR1NR3C1
SCHEMBL6209189 0.78 CYP11B2 (0.53) CYP11B2CYP11B1SMONR3C1RAB9A
SCHEMBL6183604 0.77 MMP13 (0.48) CYP11B2
SCHEMBL6183317 0.77 PGR (0.55) CYP11B2CYP11B1SMOCYP19A1NPBWR1
SCHEMBL4456778 0.75 CYP11B2 (0.50) CYP11B2CYP11B1SMONR3C1
SCHEMBL6208856 0.74 CYP11B2 (0.49) CYP11B2SMOSMN1; SMN2NPSR1RAB9A
SCHEMBL15825125 0.74 CYP11B2 (0.69) CYP11B2CYP11B1SMOCYP19A1NR3C1
SCHEMBL15839046 0.74 CYP11B2 (1.00) CYP11B2CYP11B1SMOCYP1A2NR3C1
SCHEMBL3017074 0.74 CYP11B2 (0.69) CYP11B2CYP11B1SMOCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919332-B2 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-19 US disclosed
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 CYP11B2 702/4885CYP11B1 585/4885SMO 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.